StoxGranules India vs Poly Medicure: share price & financials comparison
NSE: GRANULES vs POLYMED · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Granules India vs Poly Medicure at a glance
Granules India (GRANULES) has a market capitalisation of ₹22,182 Cr, against ₹17,041 Cr for Poly Medicure (POLYMED). Over the past year Granules India has returned +43.2%, compared with -14.0% for Poly Medicure. On valuation, Granules India trades at a lower P/E of 31.1 versus 53.5. Granules India earns a higher return on equity (10.9% vs 9.8%). Granules India comes out ahead on size, valuation, financial health and momentum. Poly Medicure comes out ahead on profitability, growth and technicals. Across the scored metrics below, Granules India leads on 10 and Poly Medicure on 8. On StoxGud's 10-point checklist, Granules India scores 8/10 and Poly Medicure scores 6/10.
| Metric | Granules India | Poly Medicure |
|---|---|---|
| Size | ||
| Market cap | ₹22,182 Cr | ₹17,041 Cr |
| Revenue (latest FY) | ₹5,366 Cr | ₹1,875 Cr |
| Net profit (latest FY) | ₹595 Cr | ₹322 Cr |
| Valuation | ||
| P/E | 31.1 | 53.5 |
| P/B | 3.38 | 5.22 |
| Dividend yield | 0.16% | 0.21% |
| Profitability | ||
| Return on equity | 10.9% | 9.8% |
| Net profit margin | 12.1% | 14.9% |
| Operating margin | 22.7% | 22.7% |
| Growth | ||
| Revenue growth (YoY) | +20.3% | +30.8% |
| Net profit growth (YoY) | +39.2% | +3.6% |
| Revenue CAGR (multi-year) | +10.6% | +19.0% |
| Financial health | ||
| Debt to equity | 0.09 | 0.12 |
| Momentum | ||
| 1-month return | -0.2% | +5.1% |
| 1-year return | +43.2% | -14.0% |
| 3-year CAGR | +30.1% | +5.8% |
| 5-year CAGR | +21.9% | +12.7% |
| 10-year CAGR | +22.7% | +24.4% |
| Distance from 52W high | -10.6% | -18.5% |
| Technicals | ||
| RSI (14) | 55 | 88 |
| Price vs 200-day avg | +8.6% | +8.8% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Granules India | Poly Medicure |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✗ |
| Score | 8/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Granules India or Poly Medicure?
Granules India has a market cap of ₹22,182 Cr and Poly Medicure has a market cap of ₹17,041 Cr as of 13 Nov 2026.
Which has a lower P/E, Granules India or Poly Medicure?
Granules India has the lower P/E: Granules India trades at 31.1 and Poly Medicure at 53.5.
Which gave better returns in the last year, Granules India or Poly Medicure?
Granules India did better: Granules India returned +43.2% and Poly Medicure returned -14.0% over one year.
What is the difference between Granules India and Poly Medicure?
Both are NSE-listed companies in Healthcare. Granules India is about 1.3 times the size of Poly Medicure by market cap. In the latest financial year Granules India reported revenue of ₹5,366 Cr and Poly Medicure ₹1,875 Cr. Operating margin is 22.7% for Granules India and 22.7% for Poly Medicure. Debt to equity is 0.09 for Granules India and 0.12 for Poly Medicure.
Which is better, Granules India or Poly Medicure?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Granules India leads on 10 and Poly Medicure on 8. Granules India is ahead on size, valuation, financial health and momentum. Poly Medicure is ahead on profitability, growth and technicals. On StoxGud's rules-based checklist Granules India scores 8/10 and Poly Medicure scores 6/10. This is information, not advice: consult a SEBI-registered adviser before investing.